Multiple Primary Cancers in Families With Li-Fraumeni Syndrome
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Li-Fraumeni syndrome is a dominantly inherited disorder characterized by early-onset breast cancer, sarcomas, and other cancers in children and young adults. Members of families with this syndrome also develop multiple primary cancers, but the frequency is unknown. To approach this issue, we quantified the incidence of second and third primary cancers in individuals from 24 Li-Fraumeni kindreds originally diagnosed with cancer during the period from 1968 through 1986. METHODS: The relative risk (RR) of subsequent cancers and 95% confidence intervals (CIs) were calculated by use of population-based incidence data from the Connecticut Cancer Registry. Kaplan-Meier analysis was used to determine the cumulative probability (+/- standard error) of subsequent cancers. RESULTS: Among 200 Li-Fraumeni syndrome family members diagnosed with cancer, 30 (15%) developed a second cancer. Eight individuals (4%) had a third cancer, while four (2%) eventually developed a fourth cancer. Overall, the RR of occurrence of a second cancer was 5.3 (95% CI = 2.8-7.8), with a cumulative probability of second cancer occurrence of 57% (+/- 10%) at 30 years after diagnosis of a first cancer. RRs of second cancers occurring in families with this syndrome were 83.0 (95% CI = 36.9-187.6), 9.7 (95% CI = 4.9-19.2), and 1.5 (95% CI = 0.5-4.2) for individuals with a first cancer at ages 0-19 years, 20-44 years, and 45 years or more, respectively. Thirty (71%) of 42 subsequent cancers in this group were component cancers of Li-Fraumeni syndrome. CONCLUSIONS: Compared with the general population, members of Li-Fraumeni syndrome families have an exceptionally high risk of developing multiple primary cancers. The excess risk of additional primary cancers is mainly for cancers that are characteristic of Li-Fraumeni syndrome, with the highest risk observed for survivors of childhood cancers. Cancer survivors in these families should be closely monitored for early manifestations of new cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Self-citationMutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Soft-Tissue Sarcomas, Breast Cancer, and Other Neoplasms: A Familial Syndrome?
LI, F. P., & FRAUMENI, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-4-747 · Cited by 1,509
Self-citationA cancer family syndrome in twenty-four kindreds.
Li, F. P., Fraumeni, J. F., Mulvihill, J. J., Blattner, W. A., Dreyfus, M., Tucker, M., & Miller, R. (1988) · PubMed · Cited by 1,293
Self-citationGerm-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W., & Chang, E. H. (1990) · Nature · doi:10.1038/348747a0 · Cited by 1,211
The Molecular Basis of Turcot's Syndrome
Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell, S. M., Krush, A. J., Berk, T., Cohen, Z., Tetu, B., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503303321302 · Cited by 1,133
Solid Cancers after Bone Marrow Transplantation
Curtis, R. E., Rowlings, P. A., Deeg, H. J., Shriner, D. A., Socié, G., Travis, L. B., Horowitz, M. M., Witherspoon, R. P., Hoover, R. N., Sobocinski, K. A., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703273361301 · Cited by 965
Self-citationStructural aspects of the p53 protein in relation to gene evolution.
Soussi, T., de Fromentel, C. C., & May, P. (1990) · PubMed · Cited by 603
Mortality From Second Tumors Among Long-Term Survivors of Retinoblastoma
Eng, C., Li, F. P., Abramson, D. H., Ellsworth, R. M., Wong, F. L., Goldman, M. B., Seddon, J., Tarbell, N., & Boice, J. D. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.14.1121 · Cited by 568
Self-citationBreast Cancer After Treatment of Hodgkin's Disease
Hancock, S. L., Tucker, M. A., & Hoppe, R. T. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.1.25 · Cited by 536
Cancer Incidence After Retinoblastoma: Radiation Dose and Sarcoma Risk
Wong, F. L. (1997) · JAMA · doi:10.1001/jama.1997.03550150066037 · Cited by 486
Analysis of relative survival and proportional mortality
Monson, R. R. (1974) · Computers and Biomedical Research · doi:10.1016/0010-4809(74)90010-x · Cited by 457
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.312 · Cited by 443
Schrag, D., Kuntz, K. M., Garber, J. E., & Weeks, J. C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362022 · Cited by 435
Self-citationCancer in the Contralateral Breast after Radiotherapy for Breast Cancer
Boice, J. D., Harvey, E. B., Blettner, M., Stovall, M., & Flannery, J. T. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203193261201 · Cited by 432
Testing for Overdispersion in Poisson and Binomial Regression Models
Dean, C. B. (1992) · Journal of the American Statistical Association · doi:10.1080/01621459.1992.10475225 · Cited by 386
Malkin, D., Jolly, K. W., Barbier, N., Look, A. T., Friend, S. H., Gebhardt, M. C., Andersen, T. I., Børresen, A.-L., Li, F. P., Garber, J., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262002 · Cited by 379
Self-citationHealth Effects of Exposure to Low Levels of Ionizing Radiation (BEIR V)
Kohn, H. I. (1990) · Radiation Research · doi:10.2307/3577873 · Cited by 376
p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis
Kemp, C. J., Wheldon, T., & Balmain, A. (1994) · Nature Genetics · doi:10.1038/ng0994-66 · Cited by 368
Li-Fraumeni syndrome – a molecular and clinical review
Varley, J., Evans, D., & Birch, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.328 · Cited by 358
Darby, S., Doll, R., Gill, S., & Smith, P. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.35 · Cited by 313
Long-term risk of sarcoma following radiation treatment for breast cancer
Taghian, A., de Vathaire, F., Terrier, P., Le, M., Auquier, A., Mouriesse, H., Grimaud, E., Sarrazin, D., & Tubiana, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90783-z · Cited by 309
Prevalence and Spectrum of Germline Mutations of the p53 Gene among Patients with Sarcoma
Toguchida, J., Yamaguchi, T., Dayton, S. H., Beaughamp, R. L., Herrera, G. E., Ishizaki, K., Yamamuro, T., Meyers, P. A., Little, J. B., Sasaki, M. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262001 · Cited by 307
Follow-up study of twenty-four families with Li-Fraumeni syndrome.
Garber, J. E., Goldstein, A. M., Kantor, A. F., Dreyfus, M., Fraumeni, J. F., & Li, F. P. (1991) · PubMed · Cited by 275
Self-citationTwo types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia
Tamiya, S., Matsuoka, M., Etoh, K., Watanabe, T., Kamihira, S., Yamaguchi, K., & Takatsuki, K. (1996) · Blood · doi:10.1182/blood.v88.8.3065.bloodjournal8883065 · Cited by 263
Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families.
Varley, J. M., McGown, G., Thorncroft, M. R., Santibanez‐Koref, M., Kelsey, A. M., Tricker, K. J., Evans, D. G., & Birch, J. M. (1997) · PubMed · Cited by 263
Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome.
Frébourg, T., Barbier, N., Yan, Y.-X., Garber, J. E., Dreyfus, M., Fraumeni, J. F., Li, F. P., & Friend, S. H. (1995) · Europe PMC (PubMed Central) · Cited by 236
Self-citationHuman T-Lymphotropic Virus Type I (HTLV-I) Seroprevalence in Jamaica
Murphy, E., Figueroa, P., Gibbs, W. N., Holding-Cobham, M., Cranston, B., Malley, K., Bodner, A. J., Alexander, S. S., & Blattner, W. A. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115824 · Cited by 199
Manns, A., & Blattner, W. A. (1991) · Transfusion · doi:10.1046/j.1537-2995.1991.31191096189.x · Cited by 174
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 155
Henry, I., Grandjouan, S., Couillin, P., Barichard, F., Huerre-Jeanpierre, C., Glaser, T., Philip, T., Lenoir, G., Chaussain, J. L., & Junien, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.9.3247 · Cited by 144
Lynch, H. T., Mulcahy, G. M., Harris, R. E., Guirgis, H. A., & Lynch, J. F. (1978) · Cancer · doi:10.1002/1097-0142(197805)41:5<2055::aid-cncr2820410554>3.0.co;2-x · Cited by 140
Lee, J. M., Abrahamson, J., Kandel, R., Donehower, L. A., & Bernstein, A. (1994) · PubMed · Cited by 115
Forty-five years of cancer incidence in Connecticut: 1935-79.
Heston, J. F., Cusano, M. M., & Young, J. L. (1986) · PubMed · Cited by 102
The Li–Fraumeni Syndrome: From Clinical Epidemiology to Molecular Genetics
Strong, L. C., Williams, W. R., & Tainsky, M. A. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116271 · Cited by 91
Are germ cell tumors part of the Li-Fraumeni cancer family syndrome?
Hartley, A. L., Birch, J. M., Kelsey, A. M., Marsden, H. B., Harris, M., & Teare, M. D. (1989) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(89)90090-3 · Cited by 82
Chemoprevention of spontaneous tumorigenesis in p53-knockout mice.
Hursting, S. D., Perkins, S. N., Haines, D. C., Ward, J. M., & Phang, J. M. (1995) · PubMed · Cited by 77
Use of logrank scores in the analysis of litter-matched data on time to tumor appearance.
Mantel, N., & Ciminera, J. L. (1979) · PubMed · Cited by 48
Eng, C., Schneider, K. A., Fraumeni, J. F., & Li, F. P. (1997) · PubMed · Cited by 42
Self-citationMcCullagh, P. J., & Nelder, J. A. (1989) · Springer eBooks · doi:10.1007/978-1-4899-3242-6_6 · Cited by 35
Identification and Management of Inherited Cancer Susceptibility
Li, F. P. (1995) · Environmental Health Perspectives · doi:10.1289/ehp.95103s8297 · Cited by 19
Self-citationVarley, J. M., Thorncroft, M. R., McGown, G., Tricker, K. J., Birch, J. M., & Evans, D. G. (1996) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(96)00059-3 · Cited by 13
Familial Aggregation of Cancer from Proband Cases with Childhood Adrenal Cortical Carcinoma1
Tsunematsu, Y., Watanabe, S., Oka, T., Tsukamoto, T., Kawa‐Ha, K., Hirata, Y., Yamanaka, H., Ohira, M., & Ono, M. (1991) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1991.tb01918.x · Cited by 11
Cited by
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,112
Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk
Easton, D. F., Pharoah, P. D. P., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., Devilee, P., Meindl, A., Couch, F. J., Southey, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501341 · Cited by 920
Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers
Bougeard, G., Renaux-Petel, M., Flaman, J.-M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugières, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.5728 · Cited by 760
“One of the striking observations was the frequency of multiple primary tumors in LFS (40%), already highlighted by several reports.(23-25) This exceptionally high incidence, the development of tumors within radiotherapy fields in 30% of mutation carriers—an observation previously reported(26,27)—and the sequential dev…”
BackgroundToro, J. R., Travis, L. B., Wu, H. J., Zhu, K., Fletcher, C. D. M., & Devesa, S. S. (2006) · International Journal of Cancer · doi:10.1002/ijc.22239 · Cited by 680
Genetic/Familial High-Risk Assessment: Breast and Ovarian
Daly, M. B., Axilbund, J. E., Buys, S., Crawford, B., Farrell, C. D., Friedman, S., Garber, J. E., Goorha, S., Gruber, S. B., Hampel, H., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0043 · Cited by 646
Self-citation
Metadata
- Authors
- Hisada, M., Garber, J. E., Li, F. P., Fung, C. Y., & Fraumeni, J. F.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-04-15
- Volume
- 90
- Issue
- 8
- Pages
- 606-611
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W1977844138
- Cited by
- 557
- References
- 49
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.